Table 4 Multivariable models of outcome for patients with pediatric CBF AML
Outcome | Variable | CBF | inv(16) | t(8; 21) | |||
|---|---|---|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | ||
CIR | Not Hispanic or Latino | 1.0 (0.4, 2.8) | 0.966 | 16 (1.7–151.8) | 0.02 | 0.3 (0.1, 1.3) | 0.095 |
FLT3-ITD positive | 4.5 (1.3, 15.6) | 0.019 | 4.2 (1.0–18.3) | 0.05 | 10.9 (0.7, 178.8) | 0.095 | |
GO treatment | 0.7 (0.3, 1.4) | 0.290 | 0.3 (0.1–0.8) | 0.02 | 1.0 (0.3, 3.7) | 0.990 | |
c-Kit Mutation | 2.2 (1.3–3.9) | 0.005 | 6.1 (1.8–20.6) | 0.04 | NA | NA | |
OS | Not Hispanic or Latino | 0.2 (0.1–0.7) | 0.01 | NA | NA | 0.1 (0.0, 0.6) | 0.01 |
FLT3-ITD positive | 21.6 (4.1–114.9) | < 0.001 | 25.9 (3.9–169.3) | < 0.001 | NA | NA | |
c-Kit Mutation Exon 8 | 0.1 (0–0.7) | 0.02 | NA | NA | NA | NA | |
c-Kit Mutation | 5.8 (1.7–19.8) | 0.01 | 0.6 (0.0, 10.7) | 0.708 | 6.2 (1.4–27.5) | 0.02 | |
Nonwhite | 0.2 (0.1–1.1) | 0.06 | 0.2 (0.0, 8.2) | 0.390 | 0.3 (0.1–1.8) | 0.18 | |
Secondary Chromosome Abnormalities | 1.9 (0.5, 7.4) | 0.36 | NA | NA | 3.7 (0.7–20.1) | 0.13 | |